{"prompt": "['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 123 of 128', '13', 'Received treatment with any non-marketed drug substance within the last 4 weeks prior to baseline', 'or 5 half-lives whichever is the longest.', '14', 'Clinically significant infection (systemic infection or serious skin infection requiring parenteral', 'treatment) within 4 weeks prior to baseline.', '15', 'Tuberculosis requiring treatment within 12 months prior to screening and/or subjects with a positive', 'blood test for tuberculosis at screening (subjects with high risk of latent tuberculosis must be tested).', '16', 'History of any known primary immunodeficiency disorder including a positive HIV test at screening,', 'or the subject taking antiretroviral medications.', '17', 'Major surgery within 8 weeks prior to screening, or planned in-patient surgery or hospitalisation', 'during the trial period.', '18', 'History of cancer.', '19', \"Any disorder which is not stable and in the investigator's opinion could affect the safety of the\", \"subject, influence the findings of the trial, or impede the subject's ability to complete the trial.\", '20', \"Any abnormal finding which in the investigator's opinion may put the subject at risk, influence the\", \"results of the trial, or influence the subject's ability to complete the trial.\", '21', 'Positive HBsAg, HBsAb, HBcAb, or anti-HCV serology at screening. Subjects with positive HBsAb', 'may be randomised provided they are hepatitis B vaccinated and have negative HBsAg and HBcAb.', '22', 'Alanine aminotransferase or aspartate aminotransferase level 2.0 times the ULN range or more at', 'screening.', '23', 'Known or suspected hypersensitivity to any component(s) of the IMP.', '24', 'Current participation in any other interventional clinical trial.', '25', 'Previously randomised in this clinical trial.', '26', 'Previously participated in a clinical trial with delgocitinib (LEO 124249).', '27', 'History of chronic alcohol or drug abuse within 12 months prior to screening, or any condition', 'associated with poor compliance as judged by the investigator.', '28', 'Employed at the trial site or directly involved with the planning or conduct of the trial, or immediate', 'family members of such individuals.', '29', 'Legally institutionalised.', '30', 'Pregnant or lactating.', 'Abbreviations: anti-HCV, hepatitis C virus antibody; HBcAb, hepatitis B core antibody; HBsAb, hepatitis B', 'surface antibody; HBsAg, hepatitis B surface antigen; HIV, human immunodeficiency virus; IGA,', \"Investigator's Global Assessment; IMP, investigational medicinal product; PDE-4, phosphodiesterase-4;\", 'ULN, upper limit of normal.']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 124 of 128', 'Appendix 5: Contact list', \"Contact details for the clinical project manager (CPM), appointed CRA, and sponsor's\", 'medical expert are provided to the trial sites as a separate contact list.', 'Sponsor', 'LEO Pharma A/S (referred to as \\'LEO\\' or \"the sponsor\\' in this clinical trial protocol) is the', 'sponsor of the clinical trial:', 'LEO Pharma A/S', 'Industriparken 55', 'DK-2750 Ballerup', 'Denmark']['Trial ID: LP0133-1273', 'Date: 07-Dec-2018', 'Version: 3.0', 'Page 125 of 128', 'Appendix 6: Protocol amendment history', 'The protocol amendment summary of changes table for the current amendment is located', 'directly before the table of contents.', 'Amendment 1 (11-Jul-2018)', 'This amendment is considered to be substantial based on the criteria set forth in Article 10(a)', 'of Directive 2001/20/EC of the European Parliament and the Council of the European Union', 'or subsequent regulation.', 'Overall rationale for the amendment', 'The main reason for the amendment is to add an exclusion criterion to ensure that subjects', 'who previously participated in a clinical trial with delgocitinib (LEO 124249) are not allowed', 'to participate in this trial. In addition, the amendment includes other changes, as presented in', 'the table below.', 'The table below presents changes made in each section and a brief rationale for each change.', 'Changes have either been summarised (written with plain text only) or marked as tracked', 'changes (new text that has been added to the protocol is highlighted in bold and text that has', 'been removed from the protocol is highlighted with a line through the text).', 'Section no. and', 'Description of change', 'Brief rationale', 'name', 'Section 4', 'The \"X\\' at Week 1 and at Week 12', 'The WLQ will be assessed less', 'Schedule of trial', 'for the WLQ questionnaire in the', 'frequently to reduce the burden on', 'procedures', 'schedule of trial procedures have', 'the trial subjects.', 'been removed.', 'Section 8.3', 'A new exclusion criterion has', 'To avoid recruitment of subjects', 'Exclusion criteria,', 'been added:', 'who have been evaluated in', 'Appendix 4:', 'Previously participated in a', 'previous delgocitinib trials.', 'Short version of', 'clinical trial with delgocitinib', 'eligibility criteria', '(LEO 124249).']\n\n###\n\n", "completion": "END"}